Polychemotherapy or gemcitabine in advanced pancreatic cancer: A meta-analysis

Digestive and Liver Disease

Volumn 46, Issue 5, 2014, Pages 452-459

  Petrelli, Fausto ^a   Coinu, Andrea ^a   Borgonovo, Karen ^a   Cabiddu, Mary ^a   Ghilardi, Mara ^a   Barni, Sandro ^a  

^a TREVIGLIO HOSPITAL   (Italy)

Author keywords

First line; Gemcitabine; Meta analysis; Overall survival; Pancreatic cancer; Polychemotherapy

Indexed keywords

CISPLATIN; FLUOROURACIL; GEMCITABINE; ANTINEOPLASTIC AGENT; BRIDGED COMPOUND; DEOXYCYTIDINE; PLATINUM DERIVATIVE; TAXANE; TAXOID;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; HUMAN; MULTICENTER STUDY; OVERALL SURVIVAL; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PUBLICATION; PUBLISHING; RANDOMIZED CONTROLLED TRIAL (TOPIC); THERAPY EFFECT; TIME TO TREATMENT; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; META ANALYSIS; PANCREATIC NEOPLASMS; SURVIVAL RATE;

ADENOCARCINOMA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRIDGED COMPOUNDS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; PANCREATIC NEOPLASMS; PLATINUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE; TAXOIDS;

EID: 84898913530     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.01.001     Document Type: Article

References (46)

1. Burris H.A., Moore M.J., Andersen J., et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Journal of Clinical Oncology 1997, 15:2403-2413.
2. Sultana A., Smith C.T., Cunningham D., et al. Meta-analyses of chemotherapy for locally advanced and metastatic pancreatic cancer. Journal of Clinical Oncology 2007, 25:2607-2615.
3. Heinemann V., Boeck S., Hinke A., et al. Metaanalysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer 2008, 8:82.
4. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology 2007, 25:1960.
5. Van Cutsem E., Vervenne W.L., Bennouna J., et al. Phase III trial of bevacizumab in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. Journal of Clinical Oncology 2009, 27:2231.
6. Philip P.A., Benedetti J., Corless C.L., et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. Journal of Clinical Oncology 2010, 28:3605.
7. Cascinu S., Berardi R., Labianca R., et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. Lancet Oncology 2008, 9:39.
8. Conroy T., Desseigne F., Ychou M., et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. New England Journal of Medicine 2011, 364:1817.
9. Von Hoff D.D., Ervin T.J., Arena F.P., et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. New England Journal of Medicine 2013, 369:1691-1703.
10. Ciliberto D., Botta C., Correale P., et al. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. European Journal of Cancer 2013, 49:593-603.
11. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998, 17:2815-2834.
12. Tierney J.F., Stewart L.A., Ghersi D., et al. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
13. Williamson P., Tudur Smith C., Hutton J.L., et al. Aggregate data meta-analysis with time-to-event outcomes. Statistics in Medicine 2002, 21:3337-3351.
14. Riess H., Helm A., Niedergethmann M., et al. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer. Journal of Clinical Oncology 2005, 23:LBA4009.
15. Ohkawa S: Randomized controlled trial of gemcitabine in combination with UFT versus gemcitabine alone in patients with advanced pancreatic cancer. Journal of Clinical Oncology 2004, 22(Suppl. 14S). (abstr. 4131).
16. Li C.P., Chao Y. A prospective randomized trial of gemcitabine alone or gemcitabine+cisplatin in the treatment of metastatic pancreatic cancer. Journal of Clinical Oncology 2004, 22:4144.
17. Viret F., Ychou M., Lepille D., et al. Gemcitabine in combination with cisplatin (GP) versus gemcitabine (G) alone in the treatment of locally advanced or metastatic pancreatic cancer: final results of a multicenter randomized phase II study. Journal of Clinical Oncology 2004, 22:4118.
18. Wang X., Ni Q., Jin M., et al. Gemcitabine or gemcitabine plus cisplatin for in 42 patients with locally advanced or metastatic pancreatic cancer. Zhonghua zhong liu za zhi 2002, 24:404-407.
19. Berlin J.D., Catalano P., Thomas J.P., et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. Journal of Clinical Oncology 2002, 20:3270-3275.
20. Colucci G., Giuliani F., Gebbia V., et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer 2002, 94:902-910.
21. Scheithauer W., Schull B., Ulrich-Pur H., et al. Biweekly high-dose gemcitabine alone or in combination with capecitabine in patients with metastatic pancreatic adenocarcinoma: a randomized phase II trial. Annals of Oncology 2003, 14:97-104.
22. Rocha Lima C.M., Green M.R., Rotche R., et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. Journal of Clinical Oncology 2004, 22:3776-3783.
23. Louvet C., Labianca R., Hammel P., et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. Journal of Clinical Oncology 2005, 23:3509-3516.
24. Reni M., Cordio S., Milandri C., et al. Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial. Lancet Oncology 2005, 6:369-376.
25. Di Costanzo F., Carlini P., Doni L., et al. Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). British Journal of Cancer 2005, 93:185-189.
26. Oettle H., Richards D., Ramanathan R.K., et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Annals of Oncology 2005, 16:1639-1645.
27. Heinemann V., Quietzsch D., Gieseler F., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. Journal of Clinical Oncology 2006, 24:3946-3952.
28. Stathopoulos G.P., Syrigos K., Aravantinos G., et al. A multicenter phase III trial comparing irinotecan-gemcitabine (IG) with gemcitabine (G) monotherapy as first-line treatment in patients with locally advanced or metastatic pancreatic cancer. British Journal of Cancer 2006, 95:587-592.
29. Poplin E., Feng Y., Berlin J., et al. Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. Journal of Clinical Oncology 2009, 27:3778-3785.
30. Abou-Alfa G.K., Letourneau R., Harker G., et al. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. Journal of Clinical Oncology 2006, 24:4441-4447.
31. Herrmann R., Bodoky G., Ruhstaller T., et al. Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. Journal of Clinical Oncology 2007, 25:2212-2217.
32. Cunningham D., Chau I., Stocken D.D., et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. Journal of Clinical Oncology 2009, 27:5513-5518.
33. Colucci G., Labianca R., Di Costanzo F., et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the GIP-1 study. Journal of Clinical Oncology 2010, 28:1645-1651.
34. Kulke M.H., Tempero M.A., Niedzwiecki D., et al. Randomized phase II study of gemcitabine administered at a fixed dose rate or in combination with cisplatin, docetaxel, or irinotecan in patients with metastatic pancreatic cancer: CALGB 89904. Journal of Clinical Oncology 2009, 27:5506-5512.
35. Dahan L., Bonnetain F., Ychou M., et al. Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301). Gut 2010, 59:1527-1534.
36. Nakai Y., Isayama H., Sasaki T., et al. A multicentre randomised phase II trial of gemcitabine alone vs gemcitabine and S-1 combination therapy in advanced pancreatic cancer: GEMSAP study. British Journal of Cancer 2012, 106:1934-1939.
37. Löhr J.M., Haas S.L., Bechstein W.O., et al. Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial. Annals of Oncology 2012, 23:1214-1222.
38. Ozaka M., Matsumura Y., Ishii H., et al. Randomized phase II study of gemcitabine and S-1 combination versus gemcitabine alone in the treatment of unresectable advanced pancreatic cancer (Japan Clinical Cancer Research Organization PC-01 study). Cancer Chemotherapy and Pharmacology 2012, 69:1197-1204.
39. Ueno H., Ioka T., Ikeda M., et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study. Journal of Clinical Oncology 2013, 31:1640-1648.
40. Trouilloud I., Dupont-Gossard A.C., Lecomte T., et al. FOLFIRI.3 (CPT-11 plus folinic acid plus 5-FU) alternating with gemcitabine or gemcitabine (G) alone in patients (pts) with previously untreated metastatic pancreatic adenocarcinoma (MPA): results of the randomized multicenter AGEO phase II trial FIRGEM. Journal of Clinical Oncology 2012, 30. (abstr. 4018).
41. Louvet C., de Gramont A., Tournigand C., et al. Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma. Cancer 2001, 91:2033-2038.
42. Sidhu R., Rong A., Dahlberg S. Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials. Clinical Cancer Research 2013, 19:969-976.
43. Ichikawa W., Sasaki Y. Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients. Annals of Oncology 2006, 17:1665-1672.
44. Vaccaro V., Bria E., Sperduti I., et al. Optimizing supportive measures for the safe administration of FOLFIRINOX as first-line treatment in advanced, inoperable pancreatic cancer (aPDAC) patients (pts) in routine clinical practice. Journal of Clinical Oncology 2012, 30. (abstr. e14661).
45. Von Hoff D.D., Ramanathan R.K., Borad M.J., et al. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a Phase I/II trial. Journal of Clinical Oncology 2011, 29:4548-4554.
46. Maréchal R., Bachet J.B., Mackey J.R., et al. Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 2012, 143:664-674.